Remodelling of Radiotherapy

Mass spectrometry for the detection of minimal residual disease (MRD) in myeloma

MASTER trial updates: Dara-KRd induction, autologous transplantation and MRD response-adapted consolidation in NDMM

Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma

Background of the KEYLYNK-007 trial for advanced solid tumours

Regulating haematopoietic stem cell dormancy and ageing through the netrin-1-neogenin axis

GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma

CARTITUDE-1: JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy for r/r multiple myeloma

Managing Hodgkin lymphoma during the COVID-19 outbreak

Working up metastatic NSCLC

Where have we got to with cancer treatment?

CART-T cell therapy in young patients with relapsed/refractory ALL